MedPath

Amoxicillin

Generic Name
Amoxicillin
Brand Names
Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500
Drug Type
Small Molecule
Chemical Formula
C16H19N3O5S
CAS Number
26787-78-0
Unique Ingredient Identifier
9EM05410Q9
Background

Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.

Amoxicillin was granted FDA approval on 18 January 1974.

Indication

Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.

Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.

Associated Conditions
Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections
Associated Therapies
-
Clinical Trials
Related News

Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy

Phase 4
Completed
Conditions
Dyspepsia
Chronic Gastritis
Gastric Cancer
Helicobacter Pylori Infection
Interventions
Drug: Berberine
Drug: Amoxicillin
Drug: Clarithromycin
Drug: Rabeprazole
Drug: Bismuth
First Posted Date
2021-01-06
Last Posted Date
2023-01-31
Lead Sponsor
Xijing Hospital of Digestive Diseases
Target Recruit Count
524
Registration Number
NCT04697186
Locations
🇨🇳

Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China

Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

Phase 4
Completed
Conditions
Gastritis
Dyspepsia
Helicobacter Pylori Infection
Gastric Cancer
Peptic Ulcer
Interventions
Drug: Esomeprazole
Drug: Bismuth
Drug: Amoxicillin
Drug: Tetracycline
Drug: Furazolidone
First Posted Date
2020-12-22
Last Posted Date
2023-01-31
Lead Sponsor
Xijing Hospital of Digestive Diseases
Target Recruit Count
658
Registration Number
NCT04678492
Locations
🇨🇳

Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China

Bismuth-Metronidazole Triple Therapy for H. Pylori First-line Treatment

Phase 4
Conditions
Helicobacter Pylori Infection
Interventions
Drug: Rabeprazole
Drug: Bismuth potassium citrate
Drug: Metronidazole
Drug: Amoxicillin
First Posted Date
2020-12-14
Last Posted Date
2020-12-22
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
270
Registration Number
NCT04667299
Locations
🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Effectiveness of Rifabutin for Treatment of Helicobacter Pylori

Phase 3
Conditions
Gastritis H Pylori
Helicobacter Infections
Resistance Bacterial
Interventions
Drug: Rifabutin
Drug: Amoxicillin
Drug: Esomeprazole
Drug: Clarithromycin
Drug: Tinidazole
First Posted Date
2020-12-03
Last Posted Date
2021-03-10
Lead Sponsor
Rabin Medical Center
Target Recruit Count
300
Registration Number
NCT04652284

Quadruple vs Tailored Therapy in the Treatment of Helicobacter Pylori Infection

Not Applicable
Completed
Conditions
Helicobacter Pylori Infection
Interventions
Drug: according to antibiogram
Drug: Amoxicillin
Drug: Metronidazole
Drug: Clarithromycin
Drug: Pantoprazole 40mg
First Posted Date
2020-11-09
Last Posted Date
2020-11-09
Lead Sponsor
University of Split, School of Medicine
Target Recruit Count
80
Registration Number
NCT04621487
Locations
🇭🇷

University hospital Split, Split, Croatia

Comparison of Three Antibiotic Protocols in Prevention of Infection in Dental Implant Surgery

Not Applicable
Completed
Conditions
Dental Implant Failed
Interventions
Drug: Amoxicillin
First Posted Date
2020-11-06
Last Posted Date
2020-11-20
Lead Sponsor
Shiraz University of Medical Sciences
Target Recruit Count
450
Registration Number
NCT04620018

Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

First Posted Date
2020-09-22
Last Posted Date
2022-01-13
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
339
Registration Number
NCT04558502

The Effect of Systemic Antibiotics on Post-surgical Complications and Patient-centered Outcomes in Patients Undergoing Implant Surgery With Guided Bone Regeneration and Simultaneous Sinus Floor Elevation

Phase 4
Recruiting
Conditions
Patients Undergoing Oral Implant Therapy
Interventions
Other: Placebo
Drug: Amoxicillin
First Posted Date
2020-09-17
Last Posted Date
2024-07-03
Lead Sponsor
Medical University of Graz
Target Recruit Count
30
Registration Number
NCT04552080
Locations
🇦🇹

Medical University of Graz, University Hospital for Dentistry and Oral Health, Graz, Austria

Pharmacokinetic Interactions of Quadruple Therapy With Anaprazole/Amoxicilin/Clarithromycin/Bismuth

Phase 1
Conditions
Healthy Male Volunteers
Interventions
Drug: Anaprazole Sodium
Drug: Amoxicillin
Drug: Clarithromycin
Drug: Bismuth
First Posted Date
2020-06-23
Last Posted Date
2020-06-23
Lead Sponsor
Sihuan Pharmaceutical Holdings Group Ltd.
Target Recruit Count
32
Registration Number
NCT04444011

Alternative Antibiotic Regimen in Periodontitis Treatment

Phase 4
Completed
Conditions
Amoxicillin
Metronidazole
Periodontitis
Ofloxacin
Root Planing
Interventions
Drug: Amoxicillin
Drug: Ofloxacin
Drug: Metronidazole
First Posted Date
2020-04-20
Last Posted Date
2020-04-20
Lead Sponsor
Istanbul Medipol University Hospital
Target Recruit Count
74
Registration Number
NCT04353362
Locations
🇹🇷

Begum Alkan, Istanbul, Turkey

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy